[Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation]

Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):691-694. doi: 10.3760/cma.j.issn.0253-2727.2022.08.014.

[Article in Chinese]

Authors

X Wang¹, X B Bao¹, J Zhang¹, B Q Song¹, M Y Li¹, J D Xie¹, H J Shen¹, D P Wu¹, H Y Qiu¹

Affiliation

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

PMID: 36709157
PMCID: PMC9593004
DOI: 10.3760/cma.j.issn.0253-2727.2022.08.014

No abstract available

MeSH terms

Antineoplastic Agents* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Isocitrate Dehydrogenase / genetics
Isocitrate Dehydrogenase / therapeutic use
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Proto-Oncogene Proteins c-bcl-2 / genetics

Substances

venetoclax
Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Proto-Oncogene Proteins c-bcl-2
IDH1 protein, human
Isocitrate Dehydrogenase